Page 24 - Confidence Interval News Today

1. In the prospective study, a dual-chamber leadless pacemaker system met primary safety endpoints at three-month follow-up. 2. The dual-chamber leadless pacemaker system provided atrial pacing and reliable atrioventricular synchrony for three months after implantation. Evidence Rating Level: 1 (Excellent) Study Rundown: Conventional pacemakers consist of a surgically implanted pulse generator with transvenous leads. Recently,

1. In this randomized controlled trial, ketamine was noninferior to electroconvulsive therapy (ECT) for reducing symptoms of treatment-resistant major depression (TRMD). 2. ECT was associated with temporarily decreased memory recall and musculoskeletal adverse effects, while ketamine was associated with dissociation. Evidence Rating Level: 1 (Excellent) Study Rundown: Major depressive disorder is a leading cause of

1. In this randomized controlled trial, the NmCV-5 vaccine elicited an immune response that was noninferior to the MenACWY-D vaccine in two-to-29-year-olds in Mali and Gambia. 2. The NmCV-5 vaccine had a similar incidence of adverse events as compared to the MenACWY-D vaccine. Evidence Rating Level: 1 (Excellent) Study Rundown: The highest incidence of meningitis and

An analysis of data from nearly 750,000 adolescents from more than 40 countries offers insight into the changing, and possibly inaccurate, perceptions of healthy body weight among younger people since the turn of the century.

1. In this retrospective cohort study, nirmatrelvir-ritonavir was effective in reducing 30-day hospitalization and mortality associated with coronavirus disease 2019 (COVID-19). 2. Molnupiravir was also associated with a reduction in 30-day mortality associated with COVID-19. Evidence Rating Level: 1 (Excellent) Study Rundown: Nirmatrelvir-ritonavir and molnupiravir received emergency use authorization from the United States Food and

Bookmark 1. In this randomized controlled trial, the NmCV-5 vaccine elicited an immune response that was noninferior to the MenACWY-D vaccine in two-to-29-year-olds in Mali and Gambia. 2. The NmCV-5 vaccine had a similar incidence of adverse events as compared to the MenACWY-D vaccine. Evidence Rating Level: 1 (Excellent) Study Rundown: The highest incidence of

1. A supervised walking program was associated with reduced discharge rates to skilled-nursing facilities (SNF) from a Veterans Affairs (VA) hospital. 2. The supervised walking program did not result in a reduced length of hospital stay or a lower number of inpatient falls. Evidence Rating Level: 1 (Excellent) Study Rundown: Inactivity during hospitalization has been

Welcome to the 2 Minute Medicine Podcast, summarizing the latest medical studies, curated and written by practicing physicians. On this podcast, twice a month, we cover the latest in healthcare news and research evidence. Our episode is live! Episode Description We begin this episode by discussing our article of the week from the New England

1. In this randomized controlled trial, the NmCV-5 vaccine elicited an immune response that was noninferior to the MenACWY-D vaccine in two-to-29-year-olds in Mali and Gambia. 2. The NmCV-5 vaccine had a similar incidence of adverse events as compared to the MenACWY-D vaccine. Evidence Rating Level: 1 (Excellent) Study Rundown: The highest incidence of meningitis

Takeda TSE 4502NYSETAK today presented favorable interim results from a global pivotal Phase 3 randomized controlled openlabel crossover trial evaluating the safety and efficacy of TAK755 recombinant ADAMTS13 replacement therapy for the prophylactic treatment of congenital thrombotic thrombocytopenic purpura cTTP and pharmacokinetics PK characteristics of TAK755 as well as longterm data on TAK755 prophylaxis from a Phase 3b continuation study.